HIF1A and carcinoma: Given that HIF-1α is a main driver of the glycolytic and catabolic state with secretion of monocarboxylates in CAFs (9), we next aimed to assess whether HIF-1α inhibition with the drug BAY 87-2243 could have an impact on the metabolism of fibroblasts and carcinoma cell aggressiveness in ADT co-cultures.